Compare IQVIA Holdings Inc. Common Stock (IQV) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQVIA Holdings Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $261.7 (market cap $42.91B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 11.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while IQVIA Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| IQV | OGN | |
|---|---|---|
Market Cap | $42.91B | $3.62B |
Volume | 1,333,456 | 2,892,999 |
Sector | Health | Health |
52-Week High | $275.02 | $13.81 |
52-Week Low | $156.66 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $57.07B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
